It was shown that down-regulation of ASCT2 function either by siRNA or by competitive inhibitors, can block the growth of cancer cells in cell-line models, as well as in vivo tumor transplants (Ni et al., 2019; Wang et al., 2015). This evidence concerns the gene SLC1A5 and neoplasm.